OSS_128167|cas:887686-02-4|西域试剂

OSS_128167,98.06%

产品编号：Bellancom-107454| CAS NO：887686-02-4| 分子式：C₁₉H₁₄N₂O₆| 分子量：366.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-107454	￥1000.00	杭州北京（现货）
Bellancom-107454	￥1450.00	杭州北京（现货）
Bellancom-107454	￥2600.00	杭州北京（现货）
Bellancom-107454	￥4400.00	杭州北京（现货）
Bellancom-107454	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

OSS_128167

产品介绍

OSS_128167 是一种有效的选择性沉默调节蛋白 6 (SIRT6) 抑制剂，对 SIRT6，SIRT1 和 SIRT2 的 IC₅₀ 分别为 89 μM，1578 μM 和 751 μM。OSS_128167 具有抗 HBV 活性，可抑制 HBV 的转录和复制。OSS_128167 具有抗癌，抗炎和抗病毒作用。

生物活性

OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.

体外研究

OSS_128167 (Compound 9; 100 µM; 0-24 hours; BxPC3 cells) treatment increases H3K9 acetylation. And also increases GLUT-1 expression in BxPC-3 cells.
OSS_128167 (Compound 9) effectively blunts phorbol myristate acetate (PMA)-induced TNF-α secretion in cultured BxPC-3 cells. OSS_128167 increases glucose uptake in cells.
OSS_128167 (100 µM; 96 hours; HepG2.2.15 and HepG2-NTCP cells) treatment significantly decreaseS HBV core DNA and 3.5-Kb RNA levels. OSS_128167 treatment also inhibits hepatitis B surface antigen (HBsAg) and hepatitis B envelope antigen (HBeAg) secretions, as well as HBsAg expression in cell lysates.
OSS_128167 (200 μM) induces chemosensitization in primary multiple myeloma (MM) cells (NCI-H929), as well as in melphalan-resistant (LR-5) and doxorubicin-resistant (Dox40) MM cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	BxPC3 cells
Concentration:	100 µM
Incubation Time:	0 hours, 2 hours, 6 hours, 18 hours, 24 hours
Result:	Increased H3K9 acetylation.

RT-PCR

Cell Line:	HepG2.2.15 and HepG2-sodium taurocholate cotransporting polypeptide (NTCP) cells
Concentration:	100 µM
Incubation Time:	96 hours
Result:	Significantly decreased HBV core DNA and 3.5-Kb RNA levels.

体内研究
(In Vivo)

OSS_128167 (50 mg/kg; intraperitoneal injection; every 4 days; for 12 days; male HBV transgenic mice) treatment markedly suppresses the level of HBV DNA and 3.5-Kb RNA in HBV transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male HBV transgenic mice (6-8-week-old)
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every 4 days; for 12 days
Result:	The level of HBV DNA and 3.5-Kb RNA were markedly suppressed in HBV transgenic mice.

体内研究

OSS_128167 (50 mg/kg; intraperitoneal injection; every 4 days; for 12 days; male HBV transgenic mice) treatment markedly suppresses the level of HBV DNA and 3.5-Kb RNA in HBV transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male HBV transgenic mice (6-8-week-old)
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every 4 days; for 12 days
Result:	The level of HBV DNA and 3.5-Kb RNA were markedly suppressed in HBV transgenic mice.

体内研究

OSS_128167 (50 mg/kg; intraperitoneal injection; every 4 days; for 12 days; male HBV transgenic mice) treatment markedly suppresses the level of HBV DNA and 3.5-Kb RNA in HBV transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male HBV transgenic mice (6-8-week-old)
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every 4 days; for 12 days
Result:	The level of HBV DNA and 3.5-Kb RNA were markedly suppressed in HBV transgenic mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 103.3 mg/mL (281.99 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7299 mL	13.6493 mL	27.2985 mL
5 mM	0.5460 mL	2.7299 mL	5.4597 mL
10 mM	0.2730 mL	1.3649 mL	2.7299 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.68 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。